Sources
Barron'sBiotech’s Rally Is Just Getting Started https://t.co/xHwWxmTvYW
Nature BiotechnologyInvesting in biotech stocks used to be seen as risky enterprise offset by the prospect of spectacular growth. But after a COVID-provoked investment peak, biotech has become part of the mainstream, according to our latest Data Page https://t.co/E2Rfkg6gih https://t.co/akzWyKGIhO
Yahoo FinanceInvestors flock back to biotech after a long, cold spell https://t.co/sDsyBsZ5Je via @WSJ
Additional media





